Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Shinji Unome"'
Autor:
Takao Miwa, Tatsunori Hanai, Sachiyo Hirata, Kayoko Nishimura, Shinji Unome, Yuki Nakahata, Kenji Imai, Yohei Shirakami, Atsushi Suetsugu, Koji Takai, Masahito Shimizu
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-7 (2024)
Abstract This study aimed to determine the relationship between animal naming test (ANT), falls, and fall-related fractures in patients with cirrhosis. Cognitive impairment and frailty were assessed using ANT and Karnofsky performance status (KPS), r
Externí odkaz:
https://doaj.org/article/5da2667f358444ea8baf846bd7cc16cf
Autor:
Kenji Imai, Koji Takai, Shinji Unome, Takao Miwa, Toshihide Maeda, Tatsunori Hanai, Yohei Shirakami, Atsushi Suetsugu, Masahito Shimizu
Publikováno v:
International Journal of Translational Medicine, Vol 2, Iss 3, Pp 345-354 (2022)
This study evaluated the factors that affect the recurrence of hepatocellular carcinoma (HCC) in hepatitis C virus (HCV)-positive patients, who had received curative treatment for initial HCC, using decision tree analysis in 111 curative cases. The e
Externí odkaz:
https://doaj.org/article/815892ddbf24474481aa5d4334bb7de2
Autor:
Takao Miwa, Tatsunori Hanai, Kayoko Nishimura, Shinji Unome, Toshihide Maeda, Yui Ogiso, Kenji Imai, Atsushi Suetsugu, Koji Takai, Masahito Shimizu
Publikováno v:
Hepatology research : the official journal of the Japan Society of HepatologyREFERENCES. 52(11)
The Global Leadership Initiative on Malnutrition (GLIM) criteria, a newly developed global consensus around core diagnostic criteria for malnutrition, needs validation studies for use in daily clinical settings. This study aimed to determine whether
Autor:
Shinji Unome, Kenji Imai, Koji Takai, Takao Miwa, Tatsunori Hanai, Yoichi Nishigaki, Hideki Hayashi, Takahiro Kochi, Shogo Shimizu, Junji Nagano, Soichi Iritani, Atsushi Suetsugu, Masahito Shimizu
Publikováno v:
Cancers; Volume 14; Issue 24; Pages: 6089
In this study, we aimed to evaluate the efficacy and safety of atezolizumab plus bevacizumab (Atez/Bev) treatment for unresectable hepatocellular carcinoma (HCC) and to analyze the factors affecting overall survival (OS). A total of 69 patients who r